One of the most comprehensive study, a meta-analysis of four individual trials of adjuvant chemotherapy in 1500 NSCLC patients (among them 300 KRAS-mutant cases), also reported that KRAS mutation had no prognostic value in this setting [8]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.